Lp-PLA2 Inhibitors for Osteoporosis Bone Density
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis and osteopenia primarily focus on reducing fracture risk and alleviating symptoms, with no cure available, and existing medications do not effectively address the underlying loss of bone mass and density.
Innovation Solution
Inhibiting the expression and activity of Lp-PLA2 protein using pharmaceutical compositions, such as reversible or irreversible inhibitors, to prevent or treat metabolic bone diseases like osteoporosis and osteopenia by reducing bone loss and density-related symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for osteoporosis focus on reducing fracture risk and alleviating symptoms, then symptom management is improved, but underlying bone mass and density loss is not effectively addressed
Solution Approach 1:
The patent extracts and targets the specific enzyme Lp-PLA2 as the root cause of bone mass loss, separating the treatment approach from general symptom management. By identifying and inhibiting this specific enzyme responsible for bone resorption, the treatment addresses the underlying pathology rather than just managing fractures and symptoms.
Solution Approach 2:
The patent employs preliminary action by inhibiting Lp-PLA2 enzyme activity before significant bone loss occurs, or at the early stages of bone deterioration. This preventive approach stops the enzymatic breakdown of bone matrix before it leads to severe osteoporosis and fractures, rather than merely treating advanced disease manifestations.
2Quantity of substance
If Lp-PLA2 inhibition is used to treat metabolic bone diseases, then bone density and bone mass are improved, but the mechanism involves complex enzymatic pathways
Solution Approach 1:
The patent uses Lp-PLA2 enzyme inhibitors as intermediary substances that block the harmful enzymatic pathway. These inhibitors act as mediators between the administered drug and the bone tissue, preventing the enzyme from breaking down bone matrix while allowing normal physiological processes to continue. This simplifies the complex enzymatic pathway intervention into a targeted molecular blockade.
Solution Approach 2:
The patent changes the biochemical parameter of Lp-PLA2 enzyme activity by introducing inhibitors that reduce or eliminate its catalytic function. This parameter change (enzyme activity level) directly translates to increased bone mass accumulation, converting a complex biochemical pathway issue into a controllable enzymatic activity parameter.
3Quantity of substance
If Lp-PLA2 inhibition is used to treat metabolic bone diseases, then bone density is increased, but the treatment requires specific pharmaceutical compositions
Solution Approach 1:
The patent employs Lp-PLA2 inhibitors that serve multiple functions: they specifically block bone-resorbing enzyme activity, prevent further bone loss, and potentially reverse existing osteoporosis. This multi-functionality is achieved through a single class of pharmaceutical compounds, simplifying the treatment approach while addressing multiple aspects of bone metabolism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhibition of Lp-PLA2 leads to increased bone density, reduced death of osteocytes and osteoblasts, and normalization of bone marrow, effectively preventing or treating metabolic bone diseases associated with bone mass and density loss.
Implementation Method 1
Lp-PLA2 is responsible for hydrolysing the sn-2 ester of oxidatively modified phosphatidylcholine to give lyso-phosphatidylcholine and an oxidatively modified fatty acid
Implementation Method 2
Lp-PLA2 plays a direct role in LDL oxidation. This is due to the poly unsaturated fatty acid-derived lipid peroxide products of Lp-PLA2 action contributing to and enhancing the overall oxidative process
Data Source
AI summary
The present invention provides compostions and methods useful for treating and preventing metabolic bone diseases and disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing metabolic bone diseases and disorders such as, for example osteoporosis, osteopenia and osteopenia related diseases and abnormal bone marrow.